Genezen
PrivateLast Round
Series C
Jul 1, 2024
Total Funding Raised
$18.5M
Company Overview
Genezen is a biotechnology company that provides contract development and manufacturing services for viral vectors used in cell and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Biotech Equipment, Quality Management
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genezen Comparables
Compare Genezen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VIVEbiotech | 90% | |
| ViroCell Biologics | 88% | |
| Andelyn Biosciences | 87% | |
Genezen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 1, 2024 | ||||
| Growth Equity | Nov 2, 2023 | ||||
| Growth Equity | Jan 5, 2021 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2025
Partnered with Humane Genomics for oncolytic virus therapy.
- Nov 7, 2025
Collaborating with Charlotte & Gwenyth Gray Foundation on CLN6 Batten Disease.
Genezen Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Genezen's valuation, stock price, and market status.